US 12,384,772 B2
Inhibitors
Ulrich Heiser, Halle (DE); Torsten Hoffmann, Halle (DE); Ingeborg Lues, Seeheim-Jugenheim (DE); and Antje Meyer, Halle (DE)
Assigned to VIVORYON THERAPEUTICS N.V., Halle (DE)
Filed by VIVORYON THERAPEUTICS N.V., Halle (DE)
Filed on May 5, 2022, as Appl. No. 17/737,602.
Application 17/737,602 is a division of application No. 16/497,040, granted, now 11,339,152, previously published as PCT/EP2018/058391, filed on Apr. 3, 2018.
Claims priority of application No. 1705263 (GB), filed on Mar. 31, 2017.
Prior Publication US 2022/0274977 A1, Sep. 1, 2022
Int. Cl. C07D 417/12 (2006.01); A61K 45/06 (2006.01); C07D 235/08 (2006.01); C07D 249/14 (2006.01); C07D 277/40 (2006.01); C07D 285/135 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 417/04 (2006.01)
CPC C07D 417/12 (2013.01) [C07D 235/08 (2013.01); C07D 249/14 (2013.01); C07D 277/40 (2013.01); C07D 285/135 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 417/04 (2013.01); A61K 45/06 (2013.01); C07B 2200/13 (2013.01)] 7 Claims
 
1. A compound of formula (XIIa):

OG Complex Work Unit Chemistry
wherein
Z is selected from CH and N;
Y1 to Y4 and Y6, Y7 and Y10 are CH;
Y5 is C;
Y8 and Y9 are C;
R5 is selected from halogen, alkyl and O-alkyl;
R6 is selected from hydrogen, alkyl and O-alkyl.